Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CEO Ryan Fukushima sold 14,286 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $70.00, for a total transaction of $1,000,020.00. Following the transaction, the chief executive officer owned 47,420 shares of the company’s stock, valued at approximately $3,319,400. The trade was a 23.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Fukushima also recently made the following trade(s):
- On Tuesday, August 18th, Ryan Fukushima sold 41,095 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total transaction of $2,038,722.95.
- On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $50.04, for a total transaction of $1,000,800.00.
- On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The shares were sold at an average price of $46.19, for a total transaction of $1,100,153.42.
- On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76.
- On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total value of $600,000.00.
Tempus AI Stock Up 3.9%
TEM opened at $68.73 on Wednesday. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The company has a market cap of $12.40 billion, a price-to-earnings ratio of -47.73 and a beta of 3.58. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $104.32. The business’s fifty day moving average is $53.57 and its two-hundred day moving average is $51.49.
Institutional Investors Weigh In On Tempus AI
A number of hedge funds and other institutional investors have recently modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Tempus AI in the second quarter valued at approximately $881,000. California State Teachers Retirement System raised its holdings in Tempus AI by 6,379.2% in the 2nd quarter. California State Teachers Retirement System now owns 6,977,205 shares of the company’s stock valued at $404,189,000 after acquiring an additional 6,869,519 shares during the last quarter. Washington Trust Advisors Inc. lifted its stake in shares of Tempus AI by 49.1% during the 2nd quarter. Washington Trust Advisors Inc. now owns 89,166 shares of the company’s stock worth $5,165,000 after purchasing an additional 29,347 shares during the period. Ameritas Advisory Services LLC purchased a new stake in shares of Tempus AI in the second quarter valued at $678,000. Finally, Straight Path Wealth Management acquired a new position in Tempus AI in the second quarter valued at $229,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of brokerages have issued reports on TEM. BTIG Research lifted their target price on shares of Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Guggenheim increased their price target on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Stifel Nicolaus dropped their price objective on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. TD Cowen restated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Finally, HC Wainwright reduced their target price on Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $65.69.
View Our Latest Stock Analysis on TEM
Tempus AI Company Profile
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Stories
- Five stocks we like better than Tempus AI
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
